Double-Edged Swords as Cancer Therapeutics: Novel, Orally Active, Small Molecules Simultaneously Inhibit p53–MDM2 Interaction and the NF-κB Pathway

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693 · see citing works

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

Activators and target genes of Rel/NF-κB transcription factors

Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727 · see citing works

Missing Pieces in the NF-κB Puzzle

Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638 · see citing works

Activators and Target Genes of Rel/NF-кB Transcription Factors

Loop, T., & Pahl, H. L. (2003) · Springer eBooks · doi:10.1007/978-94-010-0163-2_1 · Cited by 3,179 · see citing works

Blinded by the Light: The Growing Complexity of p53

Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · see citing works

p53 in health and disease

Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,275 · see citing works

Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism

Sen, R., & Baltimore, D. (1986) · Cell · doi:10.1016/0092-8674(86)90807-x · Cited by 2,029 · see citing works

Transcriptional regulation of endothelial cell adhesion molecules: NF‐κB and cytokine‐inducible enhancers

Collins, T., Read, M. A., Neish, A. S., Whitley, M. Z., Thanos, D., & Maniatis, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.10.7542214 · Cited by 1,718 · see citing works

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286 · see citing works

Multi-target therapeutics: when the whole is greater than the sum of the parts

Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105 · see citing works

Awakening guardian angels: drugging the p53 pathway

Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · see citing works

Structural Biology of the Tumor Suppressor p53

Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 699 · see citing works

Structure-based design of potent non-peptide MDM2 inhibitors

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., et al. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051147z · Cited by 657 · see citing works

Inhibitors of NF-κB signaling: 785 and counting

Gilmore, T. D., & Herscovitch, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209982 · Cited by 571 · see citing works

New Insights into the Role of Nuclear Factor-κB in Cell Growth Regulation

Chen, F., Castranova, V., & Shi, X. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61708-7 · Cited by 471 · see citing works

The p53 orchestra: Mdm2 and Mdmx set the tone

Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450 · see citing works

Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells

Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 433 · see citing works

Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors

Barnett, S. F., Defeo-Jones, D., Fu, S., Hancock, P. J., Haskell, K., Jones, R. E., Kahana, J. A., Kral, A. M., Leander, K. R., LEE, L. L., et al. (2005) · Biochemical Journal · doi:10.1042/bj20041140 · Cited by 398 · see citing works

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 389 · see citing works

The Tumor Suppressor p53: From Structures to Drug DiscoveryPreprint

Joerger, A. C., & Fersht, A. R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000919 · Cited by 356 · see citing works

p53 stabilization is decreased upon NFκB activation

Tergaonkar, V., Pando, M. P., Vafa, O., Wahl, G. M., & Verma, I. M. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00068-5 · Cited by 312 · see citing works

Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors

Gurova, K. V., Hill, J. E., Guo, C., Prokvolit, A., Burdelya, L. G., Samoylova, E. M., Khodyakova, A. V., Ganapathi, R. N., Ganapathi, M. K., Tararova, N. D., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508888102 · Cited by 266 · see citing works

Nuclear Factor-κB Activation: A Question of Life or Death

Shishodia, S., & Aggarwal, B. B. (2002) · BMB Reports · doi:10.5483/bmbrep.2002.35.1.028 · Cited by 234 · see citing works

Structural Basis for Chk1 Inhibition by UCN-01

Zhao, B., Bower, M. J., McDevitt, P. J., Zhao, H., Davis, S. T., Johanson, K., Green, S. M., Concha, N. O., & Zhou, B. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201233200 · Cited by 206 · see citing works

Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain

Popowicz, G. M., Czarna, A., & Holak, T. A. (2008) · Cell Cycle · doi:10.4161/cc.6365 · Cited by 195 · see citing works

1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a Potent Aurora Kinase Inhibitor with a Favorable Antitumor Kinase Inhibition Profile

Fancelli, D., Moll, J. K., Varasi, M., Bravo, R., Artico, R., Berta, D. G., Bindi, S., Cameron, A. D., Candiani, I., Cappella, P., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060897w · Cited by 188 · see citing works

Cyclooxygenase (COX)-2 Inhibitor Celecoxib Abrogates TNF-Induced NF-κB Activation through Inhibition of Activation of IκBα Kinase and Akt in Human Non-Small Cell Lung Carcinoma: Correlation with Suppression of COX-2 Synthesis

Shishodia, S., Koul, D., & Aggarwal, B. B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.2011 · Cited by 185 · see citing works

Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction

Rew, Y., Sun, D., de Turiso, F. G.-L., Bartberger, M. D., Beck, H. P., Canon, J. R., Chen, A., Chow, D. T., Deignan, J., Fox, B. M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300354j · Cited by 166 · see citing works

Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways

Dey, A., Tergaonkar, V., & Lane, D. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2759 · Cited by 146 · see citing works

Potent and Selective Aurora Inhibitors Identified by the Expansion of a Novel Scaffold for Protein Kinase Inhibition

Fancelli, D., Berta, D. G., Bindi, S., Cameron, A. D., Cappella, P., Carpinelli, P., Catana, C., Forte, B., Giordano, P., Giorgini, M. L., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049076m · Cited by 146 · see citing works

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives as Novel Inhibitors of p53–MDM2 Protein–Protein Interaction

Zhuang, C., Miao, Z., Zhu, L., Dong, G., Guo, Z., Wang, S., Zhang, Y., Wu, Y., Yao, J., Sheng, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300969t · Cited by 131 · see citing works

Inducible IκB Kinase/IκB Kinase ε Expression Is Induced by CK2 and Promotes Aberrant Nuclear Factor-κB Activation in Breast Cancer Cells

Eddy, S. F., Guo, S., Demicco, E. G., Romieu, R., Landesman‐Bollag, E., Seldin, D. C., & Sonenshein, G. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1602 · Cited by 127 · see citing works

Structural Biology of the Tumor Suppressor p53 and Cancer‐Associated Mutants

Joerger, A. C., & Fersht, A. R. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97001-8 · Cited by 122 · see citing works

Characterization of the Recombinant IKK1/IKK2 Heterodimer

Huynh, Q. K., Boddupalli, H., Rouw, S., Koboldt, C. M., Hall, T., Sommers, C., Hauser, S. D., Pierce, J. L., Combs, R. G., Reitz, B. A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000296200 · Cited by 65 · see citing works

Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing

Brasca, M. G., Albanese, C., Alzani, R., Amici, R., Avanzi, N. R., Ballinari, D., Bischoff, J. R., Borghi, D., Casale, E., Croci, V., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.042 · Cited by 61 · see citing works

A Novel Naturally Occurring Salicylic Acid Analogue Acts as an Anti-Inflammatory Agent by Inhibiting Nuclear Factor-kappaB Activity in RAW264.7 Macrophages

Zhang, T., Sun, L., Liu, R., Zhang, D., Lan, X., Huang, C., Xin, W., Wang, C., Zhang, D., & Du, G. (2012) · Molecular Pharmaceutics · doi:10.1021/mp2003779 · Cited by 59 · see citing works

Small-Molecule Inhibitors of p53-MDM2 Interaction: the 2006-2010 Update

Millard, M., Pathania, D., Grande, F., Xu, S., & Neamati, N. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222649 · Cited by 59 · see citing works

3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: A new class of CDK2 inhibitors

Pevarello, P., Fancelli, D., Vulpetti, A., Amici, R., Villa, M., Pittalà, V., Vianello, P., Cameron, A. D., Ciomei, M., Mercurio, C., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.10.071 · Cited by 57 · see citing works

CYP2E1 potentiation of LPS and TNFα-induced hepatotoxicity by mechanisms involving enhanced oxidative and nitrosative stress, activation of MAP kinases, and mitochondrial dysfunction

Lu, Y., & Cederbaum, A. I. (2009) · Genes & Nutrition · doi:10.1007/s12263-009-0150-5 · Cited by 52 · see citing works

The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing

Ochiana, S. O., Pandarinath, V., Wang, Z., Kapoor, R., Ondrechen, M. J., Ruben, L., & Pollastri, M. P. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.07.038 · Cited by 49 · see citing works

Structure–activity relationship and antitumor activity of thio-benzodiazepines as p53–MDM2 protein–protein interaction inhibitors

Guo, Z., Zhuang, C., Zhu, L., Zhang, Y., Yao, J., Dong, G., Wang, S., Liu, Y., Chen, H., Sheng, C., et al. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.08.003 · Cited by 40 · see citing works

Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53–MDM2 protein–protein interaction

Zhuang, C., Miao, Z., Zhu, L., Zhang, Y., Guo, Z., Yao, J., Dong, G., Wang, S., Liu, Y., Chen, H., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.09.043 · Cited by 28 · see citing works

Discovery and structural optimization of pyrazole derivatives as novel inhibitors of Cdc25B

Chen, H., Liu, Y., Wang, L., Shen, Q., Li, J. X., & Nan, F. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.040 · Cited by 25 · see citing works

Tepoxalin enhances the activity of an antioxidant, pyrrolidine dithiocarbamate, in attenuating tumor necrosis factor alpha-induced apoptosis in WEHI 164 cells.

Lee, D. H. S., MacIntyre, J. P., Taylor, G. R., Wang, E., Plante, R. K., Tam, S. S. C., Pope, B. L., & Lau, C. Y. (1999) · PubMed · Cited by 17 · see citing works

Role of nitric oxide and nuclear factor-κB in the CYP2E1 potentiation of tumor necrosis factor α hepatotoxicity in mice

Wu, D., Xu, C., & Cederbaum, A. I. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.11.001 · Cited by 16 · see citing works

Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat model

Grant, S. K., Tran, P., Zhang, Q., Zou, A., Dinh, D. M., Jensen, J. R., Zhou, S., Kang, X., Zachwieja, J., Lippincott, J., et al. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.029 · Cited by 11 · see citing works

Tepoxalin Enhances the Activity of an Antioxidant, Pyrrolidine Dithiocarbamate, in Attenuating Tumor Necrosis Factor α-Induced Apoptosis in WEHI 164 Cells

Lee, D. H. S., MacIntyre, J. P., Taylor, G. R., Wang, E. Y., Plante, R. K., Tam, S. S. C., Pope, B. L., & Lau, C. Y. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38293-x · Cited by 6 · see citing works

Chalcone: A Privileged Structure in Medicinal Chemistry

Zhuang, C., Zhang, W., Sheng, C., Zhang, W., Xing, C., & Miao, Z. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00020 · Cited by 1,486 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs

Kudlová, N., Sanctis, J. B. D., & Hajdúch, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084168 · Cited by 176 · see citing works

State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors

Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00252d · Cited by 165 · see citing works

Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections

Huang, Y., Dong, G., Li, H., Liu, N., Zhang, W., & Sheng, C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00393 · Cited by 110 · see citing works

Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives

Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.003 · Cited by 106 · see citing works

Small-molecule MDM2 inhibitors in clinical trials for cancer therapy

Wang, S., & Chen, F. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114334 · Cited by 102 · see citing works

Meeting Organocatalysis with Drug Discovery: Asymmetric Synthesis of 3,3′-Spirooxindoles Fused with Tetrahydrothiopyrans as Novel p53-MDM2 Inhibitors

Wang, S., Jiang, Y., Wu, S., Dong, G., Miao, Z., Zhang, W., & Sheng, C. (2016) · Organic Letters · doi:10.1021/acs.orglett.6b00155 · Cited by 95 · see citing works

Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer

He, S., Ma, J., Fang, Y., Liu, Y., Wu, S., Dong, G., Wang, W., & Sheng, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.022 · Cited by 91 · see citing works

Reviving the guardian of the genome: Small molecule activators of p53

Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 80 · see citing works

Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents

He, S., Dong, G., Wu, S., Fang, K., Miao, Z., Wang, W., & Sheng, C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00664 · Cited by 68 · see citing works

Highly enantioselective synthesis of fused bicyclic dihydropyranones via low-loading N-heterocyclic carbene organocatalysis

Li, J., Fu, L., Wu, J., Yang, K., Li, Q., Gou, X., Peng, C. Y., Han, B., & Shen, X. (2017) · Chemical Communications · doi:10.1039/c7cc02921g · Cited by 60 · see citing works

EGCG Enhanced the Anti-tumor Effect of Doxorubicine in Bladder Cancer via NF-κB/MDM2/p53 Pathway

Luo, K.-W., Zhu, X., Zhao, T., Zhong, J., Gao, H., Luo, X., & Huang, W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.606123 · Cited by 41 · see citing works

MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy

Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40 · see citing works

Pyrrolo[3,4-c]pyrazole Synthesis via Copper(Ι) Chloride-Catalyzed Oxidative Coupling of Hydrazones to Maleimides

Zhu, J., Wang, W.-K., Jin, Z.-H., Wang, Q., & Zhao, S. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b01641 · Cited by 40 · see citing works

Allosteric Modulators of Protein–Protein Interactions (PPIs)

Ni, D., Liu, N., & Sheng, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8719-7_13 · Cited by 37 · see citing works

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer

Li, W., Peng, X., Lang, J., & Xu, C. S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00631 · Cited by 36 · see citing works

Chemical Variations on the p53 Reactivation Theme

Ribeiro, C. J. A., Rodrigues, C. M. P., Moreira, R., & Santos, M. M. M. (2016) · Pharmaceuticals · doi:10.3390/ph9020025 · Cited by 35 · see citing works

Stereoselective Synthesis of Quaternary Pyrrolidine-2,3-diones and β-Amino Acids

Shymanska, N. V., & Pierce, J. G. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b01185 · Cited by 34 · see citing works

Recent Synthetic Approaches towards Small Molecule Reactivators of p53

Silva, J. L., Lima, C. G. S., Rangel, L. P., Ferretti, G. D. S., Pauli, F. P., Ribeiro, R. C. B., Silva, T. B., da Silva, F. D. C., & Ferreira, V. F. (2020) · Biomolecules · doi:10.3390/biom10040635 · Cited by 28 · see citing works

Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran–oxindole derivatives as potent p53-MDM2 inhibitors

Ji, C., Wang, S., Chen, S., He, S., Jiang, Y., Miao, Z., Li, J., & Sheng, C. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.07.049 · Cited by 27 · see citing works

Enantioselective synthesis of pyrano[2,3- c ]pyrrole via an organocatalytic [4 + 2] cyclization reaction of dioxopyrrolidines and azlactones

Wang, Y., Chen, Y., Li, X., Mao, Y., Chen, W., Zhan, R., & Huang, H. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob00419j · Cited by 26 · see citing works

Design, Synthesis and Biological Evaluation of Sulfamide and Triazole Benzodiazepines as Novel p53-MDM2 Inhibitors

Yu, Z., Zhuang, C., Wu, Y., Guo, Z., Li, J., Dong, G., Yao, J., Sheng, C., Miao, Z., & Zhang, W. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150915741 · Cited by 25 · see citing works

Design, synthesis and biological evaluation of novel pyrazolochalcones as potential modulators of PI3K/Akt/mTOR pathway and inducers of apoptosis in breast cancer cells

Shaik, A. B., Rao, G. K., Kumar, G. B., Patel, N., Reddy, V. S., Khan, I., Routhu, S. R., Kumar, C. G., Veena, I., Shekar, K. C., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.056 · Cited by 24 · see citing works

p53: An Attractive Therapeutic Target for Cancer

Patel, K. R., & Patel, H. D. (2019) · Current Medicinal Chemistry · doi:10.2174/1573406415666190621094704 · Cited by 24 · see citing works

Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer

Bhatia, N., Khator, R., Kulkarni, S., Singh, Y., Kumar, P., & Thareja, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867330666221114103924 · Cited by 18 · see citing works

Synthetic Strategies and Biological Potential of Coumarin-Chalcone Hybrids: A New Dimension to Drug Design

Pasricha, S., & Gahlot, P. (2020) · Current Organic Chemistry · doi:10.2174/1385272824666200219091830 · Cited by 18 · see citing works

Discovery of 1-arylpyrrolidone derivatives as potent p53–MDM2 inhibitors based on molecule fusing strategy

Li, J., Wu, Y., Guo, Z., Zhuang, C., Yao, J., Dong, G., Yu, Z., Min, X., Wang, S., Liu, Y., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.04.063 · Cited by 16 · see citing works

Synthesis of dihydropyrazolo[4,3-c]azepines via iodine-mediated intramolecular hydrative cyclization

Batchu, H., & Batra, S. (2014) · Tetrahedron Letters · doi:10.1016/j.tetlet.2014.09.073 · Cited by 15 · see citing works

Health-promoting functions and related comprehensive molecular mechanisms of tea: from the perspectives of anti-inflammatory, lipid-lowering, glucose-lowering and anti-cancer effects

Xu, J., Jia, S., Ren, Y., Zhang, Y., Zhang, J., Tang, C., Kan, J., Liu, J., & Wang, Y. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106769 · Cited by 14 · see citing works

Design, synthesis and structure–activity relationship of 4,5-dihydropyrrolo[3,4- c ]pyrazol-6(1 H )-ones as potent p53-MDM2 inhibitors

Zhou, W.-H., Xu, X., Li, J., Min, X., Yao, J., Dong, G., Zhuang, C., Miao, Z., & Zhang, W. (2016) · Chinese Chemical Letters · doi:10.1016/j.cclet.2016.09.001 · Cited by 14 · see citing works

Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR–p53–NF-κB interactions

Kwon, M., Jang, H.-J., Kim, E. H., & Roh, J. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1235104 · Cited by 13 · see citing works

A novel drug discovery strategy: Mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways

Zhuang, C., Sheng, C., Shin, W. S., Wu, Y., Li, J., Yao, J., Dong, G., Zhang, W., Sham, Y. Y., Miao, Z., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2521 · Cited by 12 · see citing works

Bisbenzimidazole derivatives as potent inhibitors of the trypsin-like sites of the immunoproteasome core particle

Koroleva, O. N., Pham, T. H., Bouvier, D., Dufau, L., Qin, L., Reboud‐Ravaux, M., Ivanov, A. A., Zhuze, A. L., Gromova, E. S., & Bouvier‐Durand, M. (2014) · Biochimie · doi:10.1016/j.biochi.2014.11.002 · Cited by 8 · see citing works

Discovery of pyrazolopyrrolidinones as potent, broad-spectrum inhibitors of Leishmania infection

Kavouris, J. A., McCall, L., Giardini, M. A., Muylder, G. D., Thomas, D. M., García-Pérez, A., Cantizani, J., Cotillo, I., Fiandor, J. M., McKerrow, J. H., et al. (2023) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2022.1011124 · Cited by 7 · see citing works

From exposure to innovation: decoding aromatic amines’ role in bladder cancer mechanisms

Xu, H., Li, J., Peng, S.-L., Bai, Y., & Tang, W. (2025) · Discover Oncology · doi:10.1007/s12672-025-02730-w · Cited by 5 · see citing works

A novel multicomponent quadruple/double quadruple domino reaction: highly efficient synthesis of polyheterocyclic architectures

Bakthadoss, M., Jayakumar, S., Selvakumar, R., Devaraj, A., & Sharada, D. S. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob02970a · Cited by 4 · see citing works

Pyrimido[4,5-b]indole Derivatives Bearing 1,2,4-oxadiazole Moiety As MDM2 Inhibitor Candidates in Cancer Treatment

Mehri, A., Mardanshahi, M., Sirous, H., Khanahmad, H., & Rostami, M. R. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0012 · Cited by 4 · see citing works

Efficient Multikilogram-Scale Synthesis of PTDSS1 Inhibitor: Development of a Practical and Scalable Optical Resolution Method for Chiral 2,3-Pyrrolidinedione

Suzuki, K., Itoh, R., Oyama, J., Hayashi, M., & Ueda, T. (2024) · Organic Process Research & Development · doi:10.1021/acs.oprd.4c00056 · Cited by 3 · see citing works

Polyhydroxy- N -alkyl-2-pyrrolidinones as a new class of glycolipid analogues with immune modulation potential

Bonam, S. R., Gorantla, J. N., Thangarasu, A. K., Lankalapalli, R. S., & Kumar, H. M. S. (2018) · Journal of Carbohydrate Chemistry · doi:10.1080/07328303.2017.1413193 · Cited by 3 · see citing works

Small molecules inhibit ex vivo tumor growth in bone

Zhou, D., Bum‐Erdene, K., Xu, D. D., Liu, D., Tompkins, D. R., Sulaiman, R. S., Corson, T. W., Chirgwin, J. M., & Meroueh, S. O. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.11.025 · Cited by 3 · see citing works

Discovery of Novel Drug-Conjugate Molecule ZM484 with Dual p53-MDM2 and TOP1 Inhibition for the Treatment of Colorectal Cancer

Wang, C., Chen, B., Yang, H., Huang, C., Zhang, Y., Yan, J., Zhang, D., Huang, A., Wu, Y., Zhu, J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01003 · Cited by 2 · see citing works

Drug Design Methods to Regulate Protein–Protein Interactions

Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_6 · Cited by 2 · see citing works

High-Throughput Screening in the Discovery of Small-Molecule Inhibitors of Protein-Protein Interactions

Zhuang, C., & Sheng, C. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_2 · Cited by 2 · see citing works

The Association and Significance of MDM2 and NF-κB Protein Expression in Multiple Myeloma

Stanić, M., Grubešić, A., Perić, Z., Jonjić, N., Seili‐Bekafigo, I., Hauser, G., Jajaš, N., & Valković, T. (2025) · Medicina · doi:10.3390/medicina61111948 · Cited by 1 · see citing works

Transformation of substituted 3-hydroxy-4-[(2E)-3-arylprop-2-enoyl]-1,5-dihydro-2H-pyrrol-2-ones by the action of I2/DMSO into derivatives 2-aryl-5,6-dihydropyrano[2,3-c]pyrrole-4,7-diones

Vydzhak, R. N., Panchishin, S. Y., Prostota, Y. O., & Броварец, В. С. (2021) · Ukrainica Bioorganica Acta · doi:10.15407/bioorganica2021.02.003

The Use of NHC Carbenes in Enantiopure Compounds Synthesis

Fernandes, R. A., Gorve, D. A., & Ranjan, R. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-32-390644-9.00071-8

Synthesis and Mechanism of p53‐MDM2 Inhibitors with Heterocyclic Structures: A Focused Review

Ji, L., Zhang, W., Zhang, Y., Zhao, S., Long, H., Qin, L., Tian, J., Li, H., Zhu, D., Zhou, Y., et al. (2023) · ChemistrySelect · doi:10.1002/slct.202302240

Microglial senescence and senolytic drugs

Ben-Azu, B., Sabbah, S., Awogbindin, I. O., Chidebe, E. O., Oritsemuelebi, B., Patel, D., Frenkel, D., & Tremblay, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27340-7.00010-3

DYNO‐MILL‐Assisted Mechanochemistry: Design of Experiments Optimization for Sustainable Synthesis of Pyrrolo[3,4‐ c ]pyrazoles

Pandey, R., Mariaux, R., Bera, S., Verma, K., Gremaud, L., & Sen, S. (2026) · ChemSusChem · doi:10.1002/cssc.70888

BindingDB Entry 50001897: Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.

BindingDB (2020) · UC San Diego · doi:10.7270/q2r213z9

BindingDB Entry 50001744: Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.

BindingDB (2020) · UC San Diego · doi:10.7270/q2rn3bdn

BindingDB Entry 50000810: Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.

BindingDB (2020) · UC San Diego · doi:10.7270/q21v5hd1

BindingDB Entry 50044472: Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.

BindingDB (2015) · UC San Diego · doi:10.7270/q2qv3p22

Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways

Dey, A., Tergaonkar, V., & Lane, D. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2759 · Cited by 146 · see citing works

Anti-Cancer Activity of a Novel Small Molecule Compound That Simultaneously Activates p53 and Inhibits NF-κB Signaling

Hwang, S. G., Park, J., Park, J. Y., Park, C. H., Lee, K.-H., Cho, J. W., Hwang, J., & Seong, J. Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044259 · Cited by 14 · see citing works

Anti-Cancer Activity of a Novel Small Molecule Compound That Simultaneously Activates p53 and Inhibits NF-kB Signaling

Hwang, S. G., Park, J., Park, J. Y., Park, C. H., Lee, K.-H., Cho, J. W., Hwang, J.-I., & Seong, J. Y. (2012)

A novel drug discovery strategy: Mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways

Zhuang, C., Sheng, C., Shin, W. S., Wu, Y., Li, J., Yao, J., Dong, G., Zhang, W., Sham, Y. Y., Miao, Z., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2521 · Cited by 12 · see citing works

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives as Novel Inhibitors of p53–MDM2 Protein–Protein Interaction

Zhuang, C., Miao, Z., Zhu, L., Dong, G., Guo, Z., Wang, S., Zhang, Y., Wu, Y., Yao, J., Sheng, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300969t · Cited by 131 · see citing works